{
    "4652298": {
        "id": 4652298,
        "significance": "1",
        "headline": "Pfizer Reports FY 2022 Results And Provides FY 2023 Financial Guidance",
        "description": "Jan 31 (Reuters) - Pfizer Inc <PFE.N>::PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE.FULL-YEAR 2023 REVENUE GUIDANCE FOR COMIRNATY OF ABOUT$13.5 BILLION AND PAXLOVID OF ABOUT $8 BILLION.FULL-YEAR 2023 REVENUES EXCLUDING COVID-19 PRODUCTS EXPECTED TO GROW 7% TO 9% OPERATIONALLY COMPARED TO FULL-YEAR 2022.INCREASING OUR INVESTMENTS BEHIND OUR LAUNCH PRODUCTS AND PIPELINE IN ORDER TO HELP REALIZE OUR GROWTH GOALS FOR 2023 AND BEYOND.EXPECT STRONG TOPLINE GROWTH OF 7% TO 9% IN 2023 EXCLUDING OUR COVID-19 PRODUCTS AND ANTICIPATED FOREIGN EXCHANGE IMPACTS.PFIZER - REVENUES FROM COVID-19 PRODUCTS EXPECTED TO GROW IN 2024 AFTER REACHING LOW POINT IN 2023 DUE TO SIGNIFICANT GOVERNMENT SUPPLY ON HAND TO START YEAR.PLANS TO MAKE SIGNIFICANT INCREMENTAL INVESTMENTS IN 2023 TO SUPPORT LAUNCH PRODUCTS AND RESEARCH AND DEVELOPMENT PROJECTS.CO REVENUES ARE ANTICIPATED TO BE LOWER IN 2023 THAN IN 2022 DUE ENTIRELY TO EXPECTED REVENUE DECLINES FOR PFIZER'S COVID-19 PRODUCTS.PFIZER - 2023 GUIDANCE FOR COMIRNATY,  PAXLOVID PRODUCTS INCLUDES  ANTICIPATED SALES THROUGH TRADITIONAL COMMERCIAL MARKETS IN U.S. IN H2 OF 2023.CURRENT FINANCIAL GUIDANCE DOES NOT ANTICIPATE ANY SHARE REPURCHASES IN 2023.FY2023 EARNINGS PER SHARE VIEW $4.43, REVENUE VIEW $74.01 BILLION -- REFINITIV IBES DATA.",
        "parentTopics": "Corporate Guidance"
    },
    "4652154": {
        "id": 4652154,
        "significance": "1",
        "headline": "Pfizer Says 2023 Paxlovid Guidance Assumes No Sales After April 1 To China",
        "description": "Jan 31 (Reuters) - Pfizer Inc <PFE.N>::PFIZER INC - 2023 PAXLOVID GUIDANCE ASSUMES NO SALES AFTER APRIL 1, 2023 TO CHINA.PFIZER SEES ESTIMATED TIMING FOR TRANSITIONING COMIRNATY AND  PAXLOVID TO COMMERCIAL MARKET IN THE U.S. IN SECOND HALF OF 2023.PFIZER  EXPECTS  ABOUT 24% OF THE U.S. POPULATION \u2013 OR 79 MILLION PEOPLE \u2013 TO RECEIVE COVID-19 VACCINE DOSES DURING 2023.PFIZER SAYS EXPECTS U.S. COVID VACCINATION RATES TO BE FLAT IN 2024 VERSUS 2023.PFIZER SEES U.S. COVID-19 VACCINATION RATES TO INCREASE IN 2025 AND 2026 IF A COMBINATION COVID\\/FLU VACCINE IS APPROVED.PFIZER SAYS EXPECTS WILL BE ABLE TO SELL PAXLOVID IN CHINA \"EFFECTIVELY UNDER GOVERNMENT REIMBURSEMENT THROUGH MARCH\".",
        "parentTopics": "Products"
    },
    "4677231": {
        "id": 4677231,
        "significance": "1",
        "headline": "Royalty Pharma Raises Full Year 2023 Guidance",
        "description": "March 15 (Reuters) - Royalty Pharma PLC <RPRX.O>::ROYALTY PHARMA RAISES FULL YEAR 2023 GUIDANCE.ROYALTY PHARMA - SEES 2023 ADJUSTED CASH RECEIPTS (NON-GAAP) TO BE BETWEEN $2,850 MILLION & $2,950 MILLION, EXCLUDING CONTRIBUTIONS FROM FUTURE TRANSACTIONS.ROYALTY PHARMA  - WILL NOW RECEIVE ROYALTIES ON NET SALES OF BOTH NURTEC ODT AND ZAVZPRET.ROYALTY PHARMA  - ANNOUNCED THAT IT HAS RECEIVED A $475 MILLION ACCELERATED MILESTONE PAYMENT FROM PFIZER, FOLLOWING U.S. FDA APPROVAL OF ZAVZPRET.Further company coverage: RPRX.O. ((Reuters.Briefs@thomsonreuters.com;)).",
        "parentTopics": "Corporate Guidance"
    },
    "4700577": {
        "id": 4700577,
        "significance": "1",
        "headline": "Pfizer Inc Says Remain On Track To Grow Our Non-COVID Revenues By 7-9% Operationally In 2023 - Prepared Remarks",
        "description": "May 2 (Reuters) - Pfizer Inc <PFE.N>::PFIZER INC - REMAIN ON TRACK TO GROW OUR NON-COVID REVENUES BY 7-9% OPERATIONALLY IN 2023- PREPARED REMARKS.PFIZER INC- STARTING IN 2025, AND CONTINUING IN 2026 AND BEYOND, WE EXPECT TO SEE AN INCREASE IN COVID-19 VACCINATION RATES.PFIZER- REGARDING PAXLOVID, CONTINUE TO EXPECT GOVERNMENT INVENTORY THAT WAS BUILT AROUND THE WORLD LAST YEAR TO BE ABSORBED BY THE END OF THIS YEAR.PFIZER - EXPECT SIGNIFICANTLY LOWER SALES CONTRIBUTIONS FROM COVID PRODUCTS IN SECOND-QUARTER VERSUS FIRST-QUARTER.PFIZER - EARLY RESULTS FROM PHASE 1 DOSE ESCALATION FOR SECOND GENERATION ORAL COVID-19 ANTIVIRAL CANDIDATE \"ENCOURAGING\".PFIZER INC- WE EXPECT COMIRNATY AND PAXLOVID SALES TO TREND MORE SEASONALLY IN 2023.PFIZER INC - PLANNING TO ADVANCE SECOND GENERATION ORAL COVID-19 ANTIVIRAL CANDIDATE TO PHASE 2 DOSE-RANGING STUDY IN H1 2023.",
        "parentTopics": "Corporate Guidance"
    },
    "4700488": {
        "id": 4700488,
        "significance": "1",
        "headline": "Pfizer Reports Q1 ADJ EPS of USD 1.23",
        "description": "May 2 (Reuters) - Pfizer Q1 revenue USD 18,282 million vs. estimate USD 16,593 million.:.",
        "parentTopics": "Corporate Guidance"
    },
    "4700566": {
        "id": 4700566,
        "significance": "1",
        "headline": "Pfizer Reaffirms Full-Year 2023 Financial Guidance",
        "description": "May 2 (Reuters) - Pfizer Inc <PFE.N>::PFIZER REPORTS FIRST-QUARTER 2023 RESULTS.REAFFIRMS FULL-YEAR 2023 FINANCIAL GUIDANCE.REVENUES ARE ANTICIPATED TO BE LOWER IN 2023 THAN IN 2022 DUE ENTIRELY TO EXPECTED REVENUE DECLINES FOR PFIZER'S COVID-19 PRODUCTS.EXCLUDING COVID-19 PRODUCTS, COMPANY CONTINUES TO EXPECT 7% TO 9% OPERATIONAL REVENUE GROWTH IN 2023.SEES 2023 COMIRNATY REVENUES OF APPROXIMATELY $13.5 BILLION, DOWN 64% FROM 2022 RESULTS.SEES 2023 PAXLOVID REVENUES OF APPROXIMATELY $8 BILLION, DOWN 58% FROM 2022 RESULTS.FY2023 EARNINGS PER SHARE VIEW $3.36, REVENUE VIEW $68.67 BILLION -- REFINITIV IBES DATA.CONTINUE TO EXPECT SEAGEN TRANSACTION TO CLOSE IN LATE 2023 OR EARLY 2024.EXPECT MAJORITY OF REVENUE GROWTH TO OCCUR IN SECOND HALF OF 2023, GIVEN TIMING OF OUR EXPECTED NEAR-TERM LAUNCHES.",
        "parentTopics": "Corporate Guidance"
    },
    "4742441": {
        "id": 4742441,
        "significance": "1",
        "headline": "Pfizer sees FY revenue USD 67,000-70,000 million",
        "description": "Aug 1 (Reuters) - Pfizer Q2 adjusted EPS USD 0.67 vs. IBES estimate USD 0.57.:.",
        "parentTopics": "Corporate Guidance"
    },
    "4742487": {
        "id": 4742487,
        "significance": "1",
        "headline": "Pfizer CEO Says Expects Start Of New COVID-19 Wave In The U.S. In The Fall",
        "description": "Aug 1 (Reuters) - Pfizer Inc <PFE.N>::PFIZER CEO SAYS 'THERE IS A HIGHER LEVEL OF UNCERTAINTY REGARDING THE DEMAND PROJECTIONS FOR OUR COVID-19 PRODUCTS THAN FOR THE REST OF THE BUSINESS'.PFIZER BELIEVES IT WILL BE ABLE TO COMMERCIALIZE ITS COVID VACCINE IN THE U.S. BEGINNING IN SEPTEMBER, ASSUMING UPDATED VACCINES APPROVED, AVAILABLE BY AUGUST-END.PFIZER CEO SAYS EXPECTS THE START OF A NEW COVID-19 WAVE IN THE US IN THE FALL.PFIZER CFO SAYS WEAKER-THAN-EXPECTED RECOMMENDATION BY CDC ADVISORS ON RSV VACCINE FOR OLDER ADULTS LIKELY TO SLOW DEMAND IN U.S..PFIZER CFO SAYS RECENT APPROVAL OF TALZENNA IN THE U.S. RESULTS IN A NARROWER-THAN-PLANNED PATIENT POPULATION.PFIZER CFO SAYS PREPARED TO LAUNCH AN ENTERPRISE-WIDE COST IMPROVEMENT PROGRAM IF COVID-19 PRODUCT REVENUES ARE LESS THAN EXPECTED.PFIZER CFO SAYS TALZENNA, RSV VACCINE, AND TORNADO DAMAGE TO ITS ROCKY MOUNT PLANT PRESENT NEAR-TERM REVENUE CHALLENGES.Further company coverage: PFE.N. ((Reuters.Briefs@thomsonreuters.com;)).",
        "parentTopics": "Corporate Guidance"
    },
    "4773038": {
        "id": 4773038,
        "significance": "1",
        "headline": "Pfizer Sees FY revenue USD 58,000 million -61,000 million",
        "description": "Oct 13 (Reuters) - Pfizer Outlook FY revenue USD 58,000-61,000 million.:.",
        "parentTopics": "Corporate Guidance"
    },
    "4773024": {
        "id": 4773024,
        "significance": "1",
        "headline": "Pfizer Amends U.S. Government Paxlovid Supply Agreement And Updates Full-Year 2023 Guidance",
        "description": "Oct 13 (Reuters) - Pfizer Inc <PFE.N>::PFIZER AMENDS U.S. GOVERNMENT PAXLOVID SUPPLY AGREEMENT AND UPDATES FULL-YEAR 2023 GUIDANCE.PFIZER INC - UPDATES FULL-YEAR 2023 GUIDANCE.PFIZER INC - REVISES 2023 REVENUE GUIDANCE RANGE TO $58.0 TO $61.0 BILLION SOLELY DUE TO COVID PRODUCTS.PFIZER INC- RECORDS $5.5 BILLION NON-CASH CHARGE IN 2023 Q3 PRIMARILY FOR COVID INVENTORY WRITE-OFFS.PFIZER INC - REVISES 2023 ADJUSTED DILUTED EPS GUIDANCE TO $1.45 TO $1.65 TO ACCOUNT FOR LOWER EXPECTED REVENUES FOR COVID PRODUCTS AND INVENTORY WRITE-OFFS.PFIZER INC - REAFFIRMS FULL-YEAR 2023 NON-COVID PRODUCT OPERATIONAL REVENUE GROWTH EXPECTATIONS OF 6% TO 8%.PFIZER INC- LAUNCHES ENTERPRISE-WIDE COST REALIGNMENT PROGRAM EXPECTED TO DELIVER TARGETED SAVINGS OF AT LEAST $3.5 BILLION.PFIZER INC - EXPECTS TO DELIVER APPROXIMATELY $1.0 BILLION IN SAVINGS IN 2023 THROUGH ITS COST REALIGNMENT PROGRAM.PFIZER INC - COMPANY IS ALSO REDUCING ITS FULL-YEAR 2023 REVENUE EXPECTATIONS FOR COMIRNATY BY APPROXIMATELY $2.0 BILLION DUE TO LOWER-THAN-EXPECTED VACCINATION RATES.PFIZER INC: REDUCES FY GUIDANCE FOR COMIRNATY REVENUES BY APPROXIMATELY $2.0 BILLION.PFIZER INC - PFIZER'S NON-COVID PRODUCTS REMAIN ON TRACK TO ACHIEVE AN EXPECTED 6% TO 8% OPERATIONAL REVENUE GROWTH YEAR OVER YEAR IN 2023..PFIZER INC- IN A NON-CASH TRANSACTION, U.S. GOVERNMENT TO RETURN ESTIMATED 7.9 MILLION EUA-LABELED PAXLOVID TREATMENT COURSES AT END OF 2023.",
        "parentTopics": "Litigation\\/Regulatory"
    },
    "4781478": {
        "id": 4781478,
        "significance": "1",
        "headline": "Pfizer Says In Qtr, RSV Vaccine, Abrysvo, Contributed $375 Mln In U.S. Revenues",
        "description": "Oct 31 (Reuters) - Pfizer Inc <PFE.N>::PFIZER INC - IN QUARTER, RECENTLY LAUNCHED RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE, ABRYSVO, CONTRIBUTED $375 MILLION IN U.S. REVENUES- PREPARED REMARKS.PFIZER INC- NEXT-GENERATION MRNA FLU\\/COVID COMBINATION CANDIDATE IS EXPECTED TO MARKET IN 2025.PFIZER INC- CONTINUE TO EXPECT THE TRANSACTION WITH SEAGEN TO CLOSE IN LATE 2023 OR EARLY 2024.PFIZER INC- CONTINUE TO EXPECT 6% TO 8% FULL YEAR OPERATIONAL REVENUE GROWTH FOR NON-COVID PRODUCTS YEAR OVER YEAR.PFIZER INC - TIMING FOR OUR STANDALONE MRNA FLU CANDIDATE IS NOW EXPECTED AFTER 2024.PFIZER INC- NOW ADVANCING OUR  FOURTH-GENERATION PCV CANDIDATE  INTO A FIRST-IN-HUMAN TRIAL, WHICH IS EXPECTED TO BEGIN IN THE FOURTH QUARTER OF 2023.PFIZER INC - ACHIEVED BOTH PRIMARY ENDPOINTS IN THE 18\u201364-YEAR-OLD COHORT OF OUR ONGOING PHASE 3 FLU TRIAL.PFIZER INC - FLU VACCINE MET SECONDARY IMMUNOGENICITY ENDPOINTS ONLY FOR A STRAINS, NOT B STRAINS OF INFLUENZA.Further company coverage: PFE.N. ((Reuters.Briefs@thomsonreuters.com;)).",
        "parentTopics": "Corporate Guidance"
    },
    "4781447": {
        "id": 4781447,
        "significance": "1",
        "headline": "Pfizer reports Q3 revenue USD 13,232 million",
        "description": "Oct 31 (Reuters) - Pfizer Q3 revenue USD 13,232 million vs. IBES estimate USD 13,341 million.:.",
        "parentTopics": "Corporate Guidance"
    },
    "4801227": {
        "id": 4801227,
        "significance": "1",
        "headline": "Pfizer Still Expects 2023 Revenue Of $58 Billion \u2013 $61 Billion",
        "description": "Dec 13 (Reuters) - Pfizer Inc <PFE.N>::PFIZER CFO SAYS STILL EXPECTS 2023 REVENUE OF $58.0 BILLION \u2013 $61.0 BILLION - CONF. CALL.PFIZER CFO SAYS EXPECTS 2023 EPS $1.45 TO $1.65 - CONF. CALL.PFIZER CFO SAYS EXPECTS 2024 COVID VACCINATION AND INFECTION RATES LARGELY CONSISTENT WITH 2023 \"BUT WE SET GUIDANCE LOWER THAN THAT\" - CONF. CALL.PFIZER CFO SAYS COMMITTED TO MAINTAINING AND GROWING DIVIDEND OVER TIME - CONF. CALL.PFIZER CFO SAYS NO LONGER EXPECTS TO HIT CAGR OF 6% FOR 2022 TO 2025 - CONF. CALL.Further company coverage: PFE.N. ((Reuters.Briefs@thomsonreuters.com;)).",
        "parentTopics": "Corporate Guidance"
    },
    "4801133": {
        "id": 4801133,
        "significance": "1",
        "headline": "Pfizer Sees Full-Year 2024 Operational Revenue Growth Of 8%-10%",
        "description": "Dec 13 (Reuters) - Pfizer Inc <PFE.N>::PFIZER PROVIDES FULL-YEAR 2024 GUIDANCE.FULL-YEAR 2024 REVENUE GUIDANCE RANGE OF $58.5 TO $61.5 BILLION INCLUDES EXPECTED CONTRIBUTION FROM SEAGEN ACQUISITION.EXPECTS FULL-YEAR 2024 OPERATIONAL REVENUE GROWTH OF 8%-10%.2024 ADJUSTED DILUTED EPS GUIDANCE RANGE OF $2.05 TO $2.25 INCLUDES EXPECTED IMPACT OF SEAGEN ACQUISITION.ENTERPRISE-WIDE COST REALIGNMENT PROGRAM NOW EXPECTED TO DELIVER ANNUAL NET COST SAVINGS OF AT LEAST $4.0 BILLION.SEAGEN EXPECTED TO CONTRIBUTE APPROXIMATELY $3.1 BILLION OF REVENUES IN FULL-YEAR 2024.ANTICIPATES APPROXIMATELY $8 BILLION IN REVENUES FOR COMIRNATY AND PAXLOVID FOR 2024.FY2024 EARNINGS PER SHARE VIEW $3.17, REVENUE VIEW $63.17 BILLION -- LSEG IBES DATA.INCLUDING IMPACT OF SEAGEN, PFIZER ANTICIPATES FULL-YEAR 2024 ADJUSTED SI&A EXPENSES TO BE IN RANGE OF $13.8 BILLION TO $14.8 BILLION.WE EXPECT OUR COST REALIGNMENT PROGRAM TO DELIVER SAVINGS OF AT LEAST $4.0 BILLION BY END OF 2024.",
        "parentTopics": "Corporate Guidance"
    },
    "4815333": {
        "id": 4815333,
        "significance": "1",
        "headline": "Pfizer Says Paxlovid Revenue Adjustment In Q1 Is Possible",
        "description": "Jan 30 (Reuters) - Pfizer Inc <PFE.N>::PFIZER SPOKESPERSON SAYS POSSIBLE THERE COULD BE REVENUE ADJUSTMENT IN Q1 FOR PAXLOVID AS WINDOW FOR U.S. GOVERNMENT RETURNS STILL OPEN.Further company coverage: PFE.N. ((Reuters.Briefs@thomsonreuters.com;)).",
        "parentTopics": "Corporate Guidance"
    },
    "4815201": {
        "id": 4815201,
        "significance": "1",
        "headline": "Pfizer Records $3.5 Bln Revenue Reversal For COVID Pill Paxlovid In Q4",
        "description": "Jan 30 (Reuters) - Pfizer Inc <PFE.N>::PFIZER CEO, IN PREPARED REMARKS, SAYS THAT CO IS FOCUSED ON EXPANDING RETAIL CONTRACTING AND OFFERINGS TO GAIN MARKET SHARE IN THE RSV VACCINE MARKET.PFIZER EXEC SAYS RECORDED $3.5 BILLION REVENUE REVERSAL FOR COVID PILL PAXLOVID IN THE FOURTH QUARTER.PFIZER SAYS Q4 RESULTS INCLUDED A $1.4 BILLION INTANGIBLE ASSET IMPAIRMENT CHARGE ASSOCIATED WITH ULCERATIVE COLITIS DRUG ETRASIMOD.PFIZER SAYS RECORDED A NEARLY $1 BILLION INTANGIBLE ASSET IMPAIRMENT FOR PNEUMOCOCCAL DISEASE PREVENTION VACCINE PREVNAR 13.Further company coverage: PFE.N. ((Reuters.Briefs@thomsonreuters.com;)).",
        "parentTopics": "Corporate Guidance"
    }
}